Improved Efficacy of Neoadjuvant Compared to Adjuvant Immunotherapy to Eradicate Metastatic Disease
Published version of a preprint
The DOI matches its Crossref record; 54 of the 55 references it cites were found in a registry or an index.
Abstract
Immunotherapy has recently entered a renaissance phase with the approval of multiple agents for the treatment of cancer. Immunotherapy stands ready to join traditional modalities, including surgery, chemotherapy, radiation, and hormone therapy, as a pillar of cancer treatment. Although immunotherapy has begun to have success in advanced cancer treatment, its scheduling and efficacy with surgery to treat earlier stages of cancer and prevent distant metastases have not been systematically examined. Here, we have used two models of spontaneously metastatic breast cancers in mice to illustrate the significantly greater therapeutic power of neoadjuvant, compared with adjuvant, immunotherapies in the context of primary tumor resection. Elevated and sustained peripheral tumor-specific immune responses underpinned the outcome, and blood sampling of tumor-specific CD8+ T cells immediately prior to and post surgery may provide a predictor of outcome. These data now provide a strong rationale to extensively test and compare neoadjuvant immunotherapy in humans. Significance: We demonstrate the significantly greater therapeutic efficacy of neoadjuvant, compared with adjuvant, immunotherapies to eradicate distant metastases following primary tumor resection. Elevated and sustained peripheral tumor-specific immune responses underpinned the outcome, and blood sampling of tumor-specific CD8+ T cells immediately prior to and post surgery may provide a predictor of outcome. Cancer Discov; 6(12); 1382–99. ©2016 AACR. See related commentary by Melero et al., p. 1312. This article is highlighted in the In This Issue feature, p. 1293
Overview
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
In the citing paper
“Data from a landmark study using an orthotopic model of breast cancer showed that neoadjuvant ICIs might outperform adjuvant ICIs106.”
From Adjuvant and neoadjuvant immunotherapies in hepatocellular carcinoma (2024) · cites this paper as [106]
In the citing paper
“Delivering ICIs after surgery enabled T cell expansion, and yielded the best antitumour activity while also decreasing toxicity106.”
From Adjuvant and neoadjuvant immunotherapies in hepatocellular carcinoma (2024) · cites this paper as [106]
Citations
Cites
Safety, activity, and immune correlates of anti–PD-1 antibody in cancer
Topalian, S. L., Hodi, F. S., Brahmer, J. R., Gettinger, S. N., Smith, D. C., McDermott, D. F., Powderly, J. D., Carvajal, R. D., Sosman, J. A., Atkins, M. B., et al. (2012) · New England Journal of Medicine · doi:10.1056/nejmoa1200690 · Cited by 12,628
Nivolumab versus docetaxel in advanced nonsquamous non-small-cell lung cancer
Borghaei, H., Paz-Ares, L., Horn, L., Spigel, D. R., Steins, M., Ready, N. E., Chow, L. Q., Vokes, E. E., Felip, E., Holgado, E., et al. (2015) · New England Journal of Medicine · doi:10.1056/nejmoa1507643 · Cited by 9,335
Combined Nivolumab and Ipilimumab or Monotherapy in Untreated Melanoma
Larkin, J., Chiarion-Sileni, V., Gonzalez, R., Grob, J. J., Cowey, C. L., Lao, C. D., Schadendorf, D., Dummer, R., Smylie, M., Rutkowski, P., et al. (2015) · New England Journal of Medicine · doi:10.1056/nejmoa1504030 · Cited by 8,157
Safety and activity of anti-PD-L1 antibody in patients with advanced cancer
Brahmer, J. R., Tykodi, S. S., Chow, L. Q. M., Hwu, W.-J., Topalian, S. L., Hwu, P., Drake, C. G., Camacho, L. H., Kauh, J., Odunsi, K., et al. (2012) · New England Journal of Medicine · doi:10.1056/nejmoa1200694 · Cited by 7,945
Mutational landscape determines sensitivity to PD-1 blockade in non–small cell lung cancer
Rizvi, N. A., Hellmann, M. D., Snyder, A., Kvistborg, P., Makarov, V., Havel, J. J., Lee, W., Yuan, J., Wong, P., Ho, T. S., et al. (2015) · Science · doi:10.1126/science.aaa1348 · Cited by 7,802
Pembrolizumab versus Ipilimumab in Advanced Melanoma
Robert, C., Schachter, J., Long, G. V., Arance, A., Grob, J. J., Mortier, L., Daud, A., Carlino, M. S., McNeil, C., Lotem, M., et al. (2015) · New England Journal of Medicine · doi:10.1056/nejmoa1503093 · Cited by 5,887
Nivolumab versus Everolimus in Advanced Renal-Cell Carcinoma
Motzer, R. J., Escudier, B., McDermott, D. F., George, S., Hammers, H. J., Srinivas, S., Tykodi, S. S., Sosman, J. A., Procopio, G., Plimack, E. R., et al. (2015) · New England Journal of Medicine · doi:10.1056/nejmoa1510665 · Cited by 5,807
The future of immune checkpoint therapy
Sharma, P., & Allison, J. P. (2015) · Science · doi:10.1126/science.aaa8172 · Cited by 4,878
Neoantigens in cancer immunotherapy
Schumacher, T. N., & Schreiber, R. D. (2015) · Science · doi:10.1126/science.aaa4971 · Cited by 4,783
Nivolumab plus Ipilimumab in Advanced Melanoma
Wolchok, J. D., Kluger, H., Callahan, M. K., Postow, M. A., Rizvi, N. A., Lesokhin, A. M., Segal, N. H., Ariyan, C. E., Gordon, R.-A., Reed, K., et al. (2013) · New England Journal of Medicine · doi:10.1056/nejmoa1302369 · Cited by 4,230
Cited by
Items 701–800 of 930
Nagl, L., Horvath, L., Salcher, S., Wolf, D. G. F., & Pircher, A. (2023) · Translational Lung Cancer Research · doi:10.21037/tlcr-23-413 · Cited by 2
Unusual Clinical Presentation of Clear Cell Sarcoma in a Young Woman
Asif, S. (2023) · ONCOLOGY · doi:10.46883/2023.25921005 · Cited by 2
Optimal Practices for Suspected Nodal Melanoma—The Role of the General Surgeon
Rog, C. J., Puzanov, I. J., & Skitzki, J. J. (2024) · JAMA Surgery · doi:10.1001/jamasurg.2023.7451 · Cited by 2
BAUDREXL, J., Sakkas, A., Pietzka, S., Derka, S., Vairaktari, G., Scheurer, M., Schramm, A. R., Wilde, F., & Ebeling, M. (2024) · Anticancer Research · doi:10.21873/anticanres.16921 · Cited by 2
Hopson, M. B., & Rashdan, S. (2024) · Frontiers in Oncology · doi:10.3389/fonc.2024.1373388 · Cited by 2
Lorusso, D., & Fucà, G. (2024) · Annals of Oncology · doi:10.1016/j.annonc.2024.09.006 · Cited by 2
Zhang, J., Song, S., Li, Y., & Gong, A. (2025) · Cancer Medicine · doi:10.1002/cam4.70617 · Cited by 2
Wang, M., Shi, M., Ding, Y., Zhang, Z., Ge, Y., Li, Z., Jing, Y., Hu, H., & Chen, X. (2025) · Frontiers in Oncology · doi:10.3389/fonc.2025.1584061 · Cited by 2
“Previous preclinical studies suggest that immunotherapy is more effective in the neoadjuvant setting than the adjuvant setting (6).”
The updated Swiss guidelines for the treatment and follow-up of cutaneous melanoma
Mangana, J., Özdemir, B. C., Mihic‐Probst, D., Siano, M., Metaxas, Y., Maul, L. V., Hunger, R. E., Lindenblatt, N., Olariu, R., von Moos, R., et al. (2025) · Swiss Medical Weekly · doi:10.57187/s.4210 · Cited by 2
Sekine, I., Aida, Y., & Suzuki, H. (2018) · Journal of Thoracic Disease · doi:10.21037/jtd.2018.09.91 · Cited by 2
Adjuvant Systemic Therapy for High-Risk Melanoma Patients
Najjar, Y. G., Massa, R. C., Sondak, V. K., Eggermont, A. M. M., Gogas, H. J., & Kirkwood, J. M. (2019) · Springer eBooks · doi:10.1007/978-3-319-46029-1_33-1 · Cited by 2
[Progress in Clinical Researches of PD-1/PD-L1 Checkpoint Inhibitor for Non-small Cell Lung Cancer].
Wu, S., Hu, C., Wu, F., Wu, Y., & Liu, P. (2019) · 中国肺癌杂志 · doi:10.3779/j.issn.1009-3419.2019.07.06 · Cited by 2
Almeida‐Santos, J., Bergman, M., Cabral, I. A., Correia, V., Caramalho, Í., & Demengeot, J. (2019) · European Journal of Immunology · doi:10.1002/eji.201948251 · Cited by 2
Hendriks, L. E. L., Remón, J., & Reck, M. (2022) · Journal of Thoracic Oncology · doi:10.1016/j.jtho.2021.11.024 · Cited by 2
Neoadjuvant Systemic Therapy for High-Risk Melanoma Patients
Keung, E. Z.-Y., Amaria, R. N., Sondak, V. K., Ross, M. I., Kirkwood, J. M., & Wargo, J. A. (2020) · Springer eBooks · doi:10.1007/978-3-030-05070-2_70 · Cited by 2
Neoadjuvant Immune Checkpoint Inhibitors in Non-small Cell Lung Cancer
Xue, C., Dong, H., Chen, Y., Lu, X., Zheng, S., & Cui, H. (2022) · Journal of College of Physicians And Surgeons Pakistan · doi:10.29271/jcpsp.2022.06.779 · Cited by 2
Bottlenecks and opportunities in immunotherapy for glioma: a narrative review
Shi, Y. K., Wu, M., Liu, Y., Chen, L., Bian, X., & Xu, C. S. (2022) · Journal of Bio-X Research · doi:10.1097/jbr.0000000000000135 · Cited by 3
“Neoadjuvant immunotherapy can also generate enhanced and sustained antitumor immune responses.[87] The immunoenhancing effect reduces tumor burden and reactivates systemic immunity, thereby improving survival over standard monotherapy.”
BackgroundNeoadjuvant Strategies for Esophageal Cancer
Barron, C. C., Wang, X., & Elimova, E. C. (2023) · Thoracic surgery clinics/Thorac. surg. clin. · doi:10.1016/j.thorsurg.2023.01.009 · Cited by 2
[Progress on Neoadjuvant Immunotherapy for Resectable Non-small Cell Lung Cancer].
Qi, C., Tian, P., & Li, W. (2024) · PubMed Central · doi:10.3779/j.issn.1009-3419.2024.102.06 · Cited by 2
“…主要包括增强对微转移灶的靶向作用和术前降低肿瘤负 荷。一方面,新辅助免疫治疗可以早期攻击微转移并减轻 肿瘤免疫抑制性 [16-19] 。 ICIs 通过阻断免疫检查点结合带来 的免疫逃逸,增加绝对淋巴细胞计数( absolute lymphocyte count, ALC ),恢复耗竭 CD8 + T 细胞的功能,诱导效应 T 细 胞的表型和功能改变,增强抗肿瘤免疫反应 [20] 。且初诊时 肿瘤细胞未暴露于治疗相关的选择压力,拥有较高的肿瘤 突变负荷( tumor mutational burden, TMB )和有限的异质 性,此时免疫治疗将得到最大获益 [21,22] 2”
Changing paradigms of non-small cell lung cancer treatment
Guerrera, F., Tabbò, F., Ruffini, E., & Bertoglio, P. (2018) · Journal of Thoracic Disease · doi:10.21037/jtd.2018.11.04 · Cited by 2
Donington, J. S. (2022) · Annals of Surgical Oncology · doi:10.1245/s10434-022-11915-4 · Cited by 2
Vacunas basadas en neoantígenos y control del cáncer: perspectivas
Moreno, R. H. M. (2020) · Revista Colombiana de Cancerología · doi:10.35509/01239015.195 · Cited by 1
Quan, R., Li, Z., Zhang, H., & Li, X. (2023) · Medicine · doi:10.1097/md.0000000000035603 · Cited by 1
“[25,26] Based on a thorough review of current clinical studies, PD-1/PD-L1 inhibitors are mainly combined with cytotoxic T lymphocyte-associated antigen 4 inhibitors, chemotherapy, targeted therapy or radiotherapy.”
BackgroundYang, H., Guo, Y., Zhao, J. Y., Zhang, Y., Jia, J., Mu, T., Hou, Z., Huang, Q., Zhang, G., Li, X., et al. (2024) · Journal of Thoracic Disease · doi:10.21037/jtd-23-1851 · Cited by 1
“The results of animal experiments showed that the survival time of mice treated with neoadjuvant immunotherapy was longer than that of mice treated with adjuvant immunotherapy (37).”
Hyngstrom, J. R. (2024) · Surgical Oncology Clinics of North America · doi:10.1016/j.soc.2024.11.003 · Cited by 1
Overcoming common emerging barriers to effective neoadjuvant immunotherapies
Sokol, S., & Bilušić, M. (2025) · Expert Review of Anticancer Therapy · doi:10.1080/14737140.2025.2474733 · Cited by 1
“For example, it allows clinicians to assess a patient’s response to therapy early on, thus providing an opportunity for modification of future treatment [5,6].”
Huang, X., You, R., Liu, F., Jian, Z., Zhou, G., Yin, H., Wu, M., Sun, T., Duan, Z., Xu, W., et al. (2025) · Cancer Immunology Immunotherapy · doi:10.1007/s00262-025-04028-w · Cited by 1
“Furthermore, investigating the immune system’s involvement in cancer may offer additional understanding into innovative therapeutic approaches [8].”
An evaluation of nivolumab and ipilimumab for the treatment of resectable stage III melanoma
McCombe, A., & van Akkooi, A. C. J. (2025) · Expert Review of Anticancer Therapy · doi:10.1080/14737140.2025.2522944 · Cited by 1
“The neo-adjuvant approach was found to have a higher therapeutic efficacy in eradicating distant metastases after surgical excision of the primary tumor [40].”
Neoadjuvant immune checkpoint inhibition improves protection against hepatic melanoma metastasis
Wohlfeil, S. A., Weller, C., Dietsch, B., Agardy, D. A., Boschert, T., Vormehr, S. A., Dormann, C., Straub, N., Häfele, V., Platten, M., et al. (2025) · Cancer Letters · doi:10.1016/j.canlet.2025.217950 · Cited by 1
The role of immunotherapy in resectable non-small-cell lung cancer
Moloney, C., & Forde, P. M. (2025) · Therapeutic Advances in Medical Oncology · doi:10.1177/17588359251361883 · Cited by 3
Efficacy of Drug Delivery Systems in Breast Cancer: A Meta-Analysis of Preclinical Animal Studies
Grapci, A. D., Selmani, P. B., Koshi, B., Bytyçi, I., & Koliqi, R. (2025) · Journal of Pharmaceutical Innovation · doi:10.1007/s12247-025-10069-6 · Cited by 1
“Conventional treatment for breast cancer typically involves a combination of surgery, radiation, and chemotherapy, often with neoadjuvant chemotherapy prior to surgery, followed by adjuvant chemotherapy [4, 5].”
Advances in Multimodality Management of Localized Non-Small Cell Lung Cancer
Jonna, S., Al‐Nusair, J., Cittolin‐Santos, G. F., & Jalal, S. I. (2025) · Seminars in Respiratory and Critical Care Medicine · doi:10.1055/a-2715-6723 · Cited by 1
“35,36 Several studies show improved outcomes with neoadjuvant immunotherapy.”
Neoadjuvant Chemoimmunotherapy
Yavuz, G., & Spicer, J. D. (2025) · Thoracic surgery clinics/Thorac. surg. clin. · doi:10.1016/j.thorsurg.2025.09.008 · Cited by 1
Tao, G., Zhang, H., Zhu, X., Teng, M., Zhou, Y., Wang, S., Bian, D., Zhang, L., Hu, H., Guo, Q., et al. (2025) · EClinicalMedicine · doi:10.1016/j.eclinm.2025.103669 · Cited by 1
Self-citationZhou, Y. X., Wei, Z., Li, M., Li, J., Meng, R., Wu, F., Jiang, G., Zhang, B., Chen, B., Zhou, C., et al. (2025) · Translational Lung Cancer Research · doi:10.21037/tlcr-2025-962 · Cited by 1
“Therefore, the combination of immunotherapy and chemotherapy as neoadjuvant treatment could generate a better pathological response (33-35).”
New paradigms in the management of melanoma throughout various stage of the disease
van Akkooi, A. C. J., & Eggermont, A. M. M. (2026) · Academia oncology. · doi:10.20935/acadonco8184 · Cited by 1
Huang, T., Guo, J., Lin, C., Kuo, H., Chuang, C.-H., Cheng, J. C., Hsu, F., Lee, J.-M., Huang, P., Liang, C., et al. (2026) · British Journal of Cancer · doi:10.1038/s41416-026-03349-6 · Cited by 1
“A preclinical study of breast cancer demonstrated the advantages of neoadjuvant therapy with immune checkpoint inhibitors (ICIs) over adjuvant ICIs [20].”
Kim, H. J. (2025) · European Journal of Cardio-Thoracic Surgery · doi:10.1093/ejcts/ezaf471 · Cited by 1
Hattenhauer, T., Mispelbaum, R., Bauernfeind, F., Feldmann, G., Baumjohann, D., Brägelmann, J., Heine, A., & Brossart, P. (2026) · Cancer Treatment Reviews · doi:10.1016/j.ctrv.2026.103157 · Cited by 1
Next-Generation Immunotherapy Strategies Driven by Tumor Microenvironment Modulation
Hui, X., Gao, G., Ding, S., Gao, S., Jiaqi, T., Xu, S., Tiesuo, Z., & Wang, H. (2026) · Immune discovery. · doi:10.70322/immune.2026.10003 · Cited by 1
Lin, J.-P., Hong, J.-H., Zhuang, F.-N., Chen, W.-J., Lin, H., He, H., Chen, Y.-J., Wang, P., Zhou, H., Wei, W., et al. (2026) · Annals of Surgical Oncology · doi:10.1245/s10434-026-19947-w · Cited by 1
“7 8–10 A meta-analysis demonstrated that adding ICIs to neoadjuvant chemotherapy significantly improved both pathological complete response (pCR) and major pathological response (MPR) rates.”
Magouliotis, D. E., Androutsopoulou, V. A., Cioffi, U., Brecher, V., Xanthopoulos, A. V., Minervini, F., & Scarci, M. (2026) · Journal of Clinical Medicine · doi:10.3390/jcm15124485 · Cited by 1
“This occurs because pCR reflects the most robust and sustained immune activation, which in turn generates the most intense secondary inflammatory-fibrotic response in the surgical field [13].”
Advances in neoadjuvant immunotherapy for non-small cell lung cancer
Liu, X., Li, H., Dong, G., Liu, Y., Ran, M., & Wang, D. (2026) · Frontiers in Immunology · doi:10.3389/fimmu.2026.1878102 · Cited by 2
“…murine models consistently demonstrate that neoadjuvant immune checkpoint blockade — whether via anti-CD25 therapy, anti-PD-1 monotherapy, or combined PD-1 blockade with CD137 stimulation — confers superior long-term survival and anti-metastatic immunity relative to adjuvant administration (20).”
Kapoor, A., Gupta, A., Sansar, B., Mishra, B. K., Menon, N. N., Shah, M., Noronha, V., & Prabhash, K. (2026) · BMC Cancer · doi:10.1186/s12885-026-16304-8 · Cited by 1
“The neoadjuvant exposure in KEYNOTE-689 may have enabled more effective priming of anti-tumor immunity while the intact tumor microenvironment and full antigenic repertoire were still present, thereby enhancing systemic immune activation and long-term immune surveillance [6, 7].”
Ye, Y., Zhang, L., Yang, Z., Huang, Y., Chen, M. L., Zhang, S., Zeng, T., Chen, C., & Zheng, B. (2026) · Frontiers in Immunology · doi:10.3389/fimmu.2026.1825905 · Cited by 1
“In NIC, this combination takes advantage of the intact tumor as an in situ source of antigen, potentially generating a more comprehensive and durable immune response (38).”
Yavuz, G., Wang, M., Spicer, J. D., Cascone, T., & Corona-Cruz, J. F. (2026) · American Society of Clinical Oncology Educational Book · doi:10.1200/edbk-26-519336 · Cited by 3
Is uniform D2 still biologically optimal in gastric cancer? Lymphadenectomy in the immunotherapy era
Polkowski, W. P., & Wyrwicz, L. S. (2026) · European Journal of Surgical Oncology · doi:10.1016/j.ejso.2026.112097 · Cited by 1
Yang, C., Song, X., Sun, H., Chen, M., & Zhu, X. (2026) · Frontiers in Immunology · doi:10.3389/fimmu.2026.1947595 · Cited by 1
Zhenyan, W., & Wang, Y. (2026) · Clinical Case Reports · doi:10.1002/ccr3.73598 · Cited by 1
Long, G. V., da Silva, I. P., Perry, K. J., Romano, J., Lo, S., Grover, P., Ascierto, P. A., Amaria, R. N., Hieken, T. J., Robert, C., et al. (2026) · Nature Medicine · doi:10.1038/s41591-026-04677-z · Cited by 1
Klempner, S. J., Wu, W., Mehta, P., Schrock, A. B., Chao, J., & Ali, S. M. (2017) · JCO Precision Oncology · doi:10.1200/po.17.00166 · Cited by 1
[Progress in Neoadjuvant Immunotherapies for Resectable Non-small Cell Lung Cancer].
Wang, S., & Mao, Y. (2020) · PubMed Central · doi:10.3779/j.issn.1009-3419.2020.103.07 · Cited by 1
Pulmonary resection after immunotherapy
Sasankan, P., Hyde, J., Wang, S., Geraci, T. C., & Cerfolio, R. J. (2021) · Journal of Visualized Surgery · doi:10.21037/jovs.2020.03.07 · Cited by 1
Neoadjuvant immunotherapy in early stage non-small cell lung cancer
Chan, K. K. L., Sim, V., Billè, A., & Zaki, K. A. (2021) · AME Medical Journal · doi:10.21037/amj-20-183 · Cited by 1
Immunotherapy and Radiotherapy: New Strategies
Campbell, A. M., & Decker, R. H. (2021) · Current cancer research · doi:10.1007/978-3-030-74028-3_10 · Cited by 1
Liver Cancer - Genesis, Progression and Metastasis
Feitelson, M. A., & Arzumanyan, A. L. (2022) · IntechOpen eBooks · doi:10.5772/intechopen.100845 · Cited by 1
Li, X., Xia, C., Liu, M., Liu, J., Dong, M., Zhao, H., Xu, S., Wang, D., Wei, S., Song, Z., et al. (2022) · Frontiers in Oncology · doi:10.3389/fonc.2022.843116 · Cited by 1
“Compa r ed to ad ju van t th e r apy , n eoad juvan t immunotherapy may improve efficacy by reducing metastasis or recurrence in early-stage NSCLC (20).”
BackgroundSelf-citationHorno, I. M., Viteri, S., Rubinstein, P., Maestre, J., Alvarado, A., Koptseva, I., Simonetti, S., Lugo, N., Cisneros, J. L., & Rosell, R. (2018) · EMJ Respiratory · doi:10.33590/emjrespir/10311519 · Cited by 1
Induction treatment in operable non-small cell lung cancer: the immune oncology era unfolds
Walker, P. R. (2023) · Journal of Thoracic Disease · doi:10.21037/jtd-23-699 · Cited by 1
(Neo)adjuvant approaches in lung cancer—paving the road to a cure
Wass, R. E., Hochmair, M. J., Lang, D., Horner, A., & Lamprecht, B. (2024) · memo - Magazine of European Medical Oncology · doi:10.1007/s12254-023-00949-3 · Cited by 1
Exploring the Role and Prognostic Value of TMEM208 in Head and Neck Squamous Cell Carcinoma
Yang, J., & Song, T. (2024) · Asian Pacific Journal of Cancer Prevention · doi:10.31557/apjcp.2024.25.3.909 · Cited by 1
“In addition, the use of ICI in neoadjuvant therapy is being actively investigated [9-11].”
BackgroundPardo, D., Viola, L., Zuluaga, J. A., Rojas, L., Bobadilla, I., Martínez, S., Bustillo, I., García-Herreros, L. G., Zapata, R., Serna, A., et al. (2023) · Medicina · doi:10.56050/01205498.2316 · Cited by 2
Le, U., Ohm, B., & Schmid, S. (2024) · Zentralblatt für Chirurgie - Zeitschrift für Allgemeine Viszeral- Thorax- und Gefäßchirurgie · doi:10.1055/a-2353-6336 · Cited by 1
“Die ,”
Hansen, T., Hill, J., Tincknell, G., Siu, D. H. W., Brungs, D., Clingan, P. R., Chantrill, L. A., & Nindra, U. (2024) · Exploration of Targeted Anti-tumor Therapy · doi:10.37349/etat.2024.00273 · Cited by 1
Xie, X., Zhang, H., He, H., Wu, B., Chen, Y., Lin, W., Feng, Q., & Chen, Q. (2024) · Frontiers in Medicine · doi:10.3389/fmed.2024.1517001 · Cited by 1
Characteristic of Immunotherapy Trials in Head and Neck Squamous Cell Carcinoma: 2013–2023
Xia, B., Wu, F., Wei, B., Li, Q., Lin, H., Lu, P., Xie, Z., Liu, N., Wu, J., Zhong, J., et al. (2025) · Oral Diseases · doi:10.1111/odi.15251 · Cited by 1
“…(cetuximab, platinum, and 5-fluorouracil), which is a category 1 regimen recommended by the National Comprehensive Cancer Network (NCCN) (Burtness et al. 2019 trials involving surgery, indicating its increasing popularity due to numerous advantages (Kanani, Veen, and Søreide 2021; Liu et al. 2016).”
Stellato, M., Rota, S., Claps, M., Guadalupi, V., Rametta, A., Fotia, G., Barella, M., Verzoni, E., & Procopio, G. (2025) · Clinical Genitourinary Cancer · doi:10.1016/j.clgc.2025.102328 · Cited by 1
Neoadjuvant PD-1 blockade in lung cancer: we’re not in Kansas anymore
Cohen, B., & Marshall, M. B. (2018) · Journal of Thoracic Disease · doi:10.21037/jtd.2018.07.98 · Cited by 1
Time may Heal All Wounds, but While It Does, Melanoma Marches on
Ollila, D. W., & Meyers, M. O. (2019) · Annals of Surgical Oncology · doi:10.1245/s10434-019-07674-4 · Cited by 1
The path forward in early-stage lung cancer
Cuppens, K., & Baas, P. (2022) · Translational Lung Cancer Research · doi:10.21037/tlcr-22-546 · Cited by 1
Zhao, Q., & Zhou, Y. (2024) · Journal of Surgical Oncology · doi:10.1002/jso.27864 · Cited by 1
“For instance, neoadjuvant chemotherapy may influence the tumor microenvironment by enhancing the body's immune response, potentially affecting microvascular invasion and indirectly influencing platelet count and function [2, 3].”
Zhang, Y., & Wang, J. (2026) · bioRxiv (Cold Spring Harbor Laboratory) · doi:10.64898/2026.09.22.753629 · Cited by 1
“The superior efficacy of neoadjuvant over adjuvant chemoimmunotherapy in eradicating metastasis diseases in the 4T1 model is consistent with previous reports (35,36).”
In the literature: February 2017
Cervantes, A. M. R., & Terol, M. J. (2017) · ESMO Open · doi:10.1136/esmoopen-2017-000171
Actualités et perspectives concernant l’immunothérapie au cours des CBNPC
Mignard, X., Chaabane, N., Chapron, J., Giraud, F., Arrondeau, J., Fabre, E., Damotte, D., Alifano, M., Goldwasser, F., & Wislez, M. (2018) · Revue des Maladies Respiratoires Actualités · doi:10.1016/s1877-1203(18)30006-5
Neoadjuvant Anti-PD-1 Immunotherapy Leads to Survival Benefit in Recurrent Glioblastoma
Newman, W. C., & Amankulor, N. (2019) · Neurosurgery · doi:10.1093/neuros/nyz174
[Promise of Neoadjuvant Immunotherapy in Resected Non-small Cell Lung Cancer].
Yao, S., & Zhang, Y. (2020) · PubMed Central · doi:10.3779/j.issn.1009-3419.2020.01.09
Mise en place: toward neoadjuvant chemoimmunotherapy for early triple-negative breast cancer
van Dongen, M. G. J., & Kok, M. (2020) · Annals of Oncology · doi:10.1016/j.annonc.2020.02.014
[Precise combination of systemic therapy and hepatic surgery].
Sun, H. (2020) · Zhonghua ganzangbing zazhi · doi:10.3760/cma.j.cn501113-20201022-00570
Wislez, M., Wang, P., Damotte, D., Goldwasser, F., & Alifano, M. (2020) · Revue des Maladies Respiratoires Actualités · doi:10.1016/s1877-1203(20)30151-8
Regulation of Anti-Tumor Immunity and Immunotherapy Response In Colorectal Cancer
Zhao, X. (2020) · University of Minnesota Digital Conservancy (University of Minnesota)
Industrial Perspective on Immunotherapy
Ravasio, S. (2021) · Advances in experimental medicine and biology · doi:10.1007/978-3-030-58174-9_15
Singla, N., Pierorazio, P. M., Allaf, M. E., & Ged, Y. M. A. (2021) · European Urology · doi:10.1016/j.eururo.2021.04.025
Immunochemotherapy as induction treatment in Stage III (N2, N3) Non-small cell lung cancerPreprint
Deng, H., Liang, H., Wang, W., Li, J., Xiong, S., Cheng, B., Li, C., Ai, Q., Chen, Z., Wang, H., et al. (2021) · medRxiv · doi:10.1101/2021.06.03.21257757
Inmunoterapia en oncología de las vías aerodigestivas superiores
Mirghani, H., & Clatot, F. (2021) · EMC - Otorrinolaringología · doi:10.1016/s1632-3475(21)45401-9
Mennecier, B., Olland, A., Mascaux, C., & Falcoz, P. (2021) · European Journal of Cardio-Thoracic Surgery · doi:10.1093/ejcts/ezab399
Wang, Z., Zhu, X., & Song, Y. (2021) · Journal for ImmunoTherapy of Cancer · doi:10.1136/jitc-2021-sitc2021.467
Evolution of Neoadjuvant Therapy in Melanoma
Fawaz, B., Rasic, G., & Sachs, T. E. (2021) · Springer eBooks · doi:10.1007/978-3-030-82639-0_9
めざす子どもの姿と連動させた道徳の授業づくりを核にせよ (特集 「道徳の時間」の改革・充実を図る) -- (学級経営と運動させた道徳教育のプランづくり)
鈴木, 健. (2009) · 現代教育科学
Misticismo y Melancolía: Reforma de los cuidados de salud mental en la España moderna
Martínez, M. A. (2004) · Revista ROL de enfermería · Cited by 1
Orthopaedic outcome measures and the SF-36. Integrating health outcome measurement in routine care
Krishnan, J. B., & Chipchase, L. S. (1996)
Safety of Immune Checkpoint Inhibitors in the Peri-operative Setting
Ahmed, M. E., Joshi, V. B., & Spiess, P. E. (2022) · Springer eBooks · doi:10.1007/978-3-030-80546-3_18
Alsawah, F., & Uprety, D. (2022) · International Journal of Cancer Care and Delivery · doi:10.53876/001c.32276
Kidney Cancer Research Highlights from ASCO GU 2022 Meeting
Ged, Y. M. A., & Singla, N. (2022) · Kidney Cancer Journal · doi:10.52733/kcj20n1-gu1
Li, B., Zhang, G., Jin, C., Zhao, Y., Hua, P., & Tong, T. (2022) · Indian Journal of Surgery · doi:10.1007/s12262-022-03389-1
Publications from Juntendo University Graduate School of Medicine, 2016 [5/6]
(2019) · Juntendō Igaku/Juntendo igaku · doi:10.14789/jmj.2019.65.1-pl
Neoadjuvant Systemic Therapy for High-Risk Melanoma Patients
Keung, E. Z.-Y., Amaria, R. N., Sondak, V. K., Ross, M. I., Kirkwood, J. M., & Wargo, J. A. (2018) · Springer eBooks · doi:10.1007/978-3-319-46029-1_70-1
Wislez, M. (2022) · Revue des Maladies Respiratoires Actualités · doi:10.1016/s1877-1203(22)00011-8
Real World Study of Immune-Related Adverse Events Caused by PD-1 Inhibitors
陈, 运. (2022) · Advances in Clinical Medicine · doi:10.12677/acm.2022.126856
Mouse Tumor Homografts Recapitulate Human Molecular Pathogenesis
Kumari, R., Ouyang, D. X., & Li, H. (2022) · Wiley eBooks · doi:10.1002/9781119535331.ch3
Immunotherapy in Early Stage Non-Small Cell Lung Cancer
Ramanarayanan, J., & Ganapathy, K. (2022) · Advances in Lung Cancer · doi:10.4236/alc.2022.113003
Metadata
- Authors
- Liu, J., Blake, S. J., Yong, M. C. R., Harjunpää, H., Ngiow, S. F., Takeda, K., Young, A., O'Donnell, J. S., Allen, S., Smyth, M. J., & Teng, M. W. L.
- Affiliations
- The University of Queensland (AU)
- QIMR Berghofer Medical Research Institute (AU)
- Juntendo University (JP)
- 1Cancer Immunoregulation and Immunotherapy Laboratory, QIMR Berghofer Medical Research Institute, Herston, Queensland, Australia.
- Corresponding author
- Teng, Michele W.L.
- ORCID
- Venue
- Cancer Discovery
- Published
- 2016-12-01
- Volume
- 6
- Issue
- 12
- Pages
- 1382-1399
- ISSN
- 2159-8274 (ISSN-L)
- 2159-8290
- OpenAlex
- W2521503673
- Cited by
- 894
- References
- 55
- Citations by year
- 2026: 86 · 2025: 91 · 2024: 135 · 2023: 112 · 2022: 113 · 2021: 112 · 2020: 101 · 2019: 65 · 2018: 50 · 2017: 23 · 2016: 1
- FWCI
- 24.99
- Type
- journal article
- Language
- en
- Open access
- closed
- Locations
- Cancer Discovery (publishedVersion)
- PubMed (publishedVersion)
- Funders
- Japan Society for the Promotion of Science (15K14410)
- Topics
- Health Sciences › Medicine › Oncology › Cancer Immunotherapy and Biomarkers
- Life Sciences › Immunology and Microbiology › Immunology › Immunotherapy and Immune Responses
- Life Sciences › Immunology and Microbiology › Immunology › T-cell and B-cell Immunology
- Keywords
- neoadjuvant immunotherapy, adjuvant immunotherapy, metastatic breast cancer, primary tumor resection, tumor-specific immunity, CD8+ T cells, predictive biomarkers
- MeSH terms
- Animals, Antibodies, Monoclonal, Antineoplastic Agents, Breast Neoplasms, Female, Humans, Immunotherapy, Neoplasm Metastasis, Treatment Outcome, Chemotherapy, Adjuvant, CD8-Positive T-Lymphocytes, Neoadjuvant Therapy, Xenograft Model Antitumor Assays, Cell Line, Tumor, Mice
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.